Excerpt: The contamination of the U.S. heparin supply has been linked by the FDA and other authorities to intentional adulteration during the manufacture of heparin in China. … The committee’s investigation indicates that the U.S. heparin supply is stressed, and could well be in shortage. China’s heparin market is experiencing its own pressures, and Smithfield Foods under Shuanghui control may be pressured to export its crude heparin product to China instead of supplying U.S. companies. The impact of this pending acquisition on the availability of U.S. heparin is critical.
To read the letter, click here.
To read a related press release, click here.